Voigtlander Christian B. sold $1.6M of ICUI

Voigtlander Christian B. (Chief Operating Officer) sold 8,929 shares of ICU MEDICAL INC/DE (ICUI) at $182.93 ($1.63M total) on 2026-08-11.

Original reporting
SEC EDGAR · Voigtlander Christian B.
Published Aug 11, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ICUI
Neutral
medium confidence
Mentioned
$ICUI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and resulting holdings after the trade. This can influence short-term sentiment but does not change the company’s disclosed fundamentals.

02

Market read

A $1.63M insider sale may draw attention from short-term traders, but it is unlikely to drive a durable repricing without additional company news.

03

What to watch

No 10b5-1 plan is mentioned, but the filing alone does not confirm intent. Traders may want to compare with prior insider activity patterns and total insider ownership changes over time.

Relevance 6/10Novelty 4/10Timing: SEC Form 4 filed on 2026-08-11 (after-hours)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for ICU Medical, Inc.

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

ICU Medical COO Voigtlander sold 8,929 shares in an open-market transaction worth about $1.63M, per an SEC Form 4 filed today.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless accompanied by other company-specific news.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new operational, financial, or regulatory information. Insider sales are common and often not predictive without additional context.

Market effects

Minimal. Insider sales in a single medtech name typically do not reset sector expectations without corroborating fundamentals.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management rather than a negative signal, especially since the article provides no accompanying negative company development.

Key entities

  • ICU Medical, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Voigtlander Christian B.

    Chief Operating Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICUIHighAI 8/10

ICU Medical (ICUI) Q3 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q3 2026 adjusted EPS of $2.44, up 20% YoY, with adjusted EBITDA at $114M. Revenue growth was driven by consumables (+5%) and IV systems (+11%), while Vital Care declined (-10%). The company expects full-year EBITDA and EPS to be at the higher end of previous guidance.

$ICUIMedAI 8/10

ICU Medical Inc (ICUI) Q3 2026 Earnings Call Highlights: Record Sales, 20% EPS Growth

ICU Medical Inc reported Q3 2026 earnings with 11% growth in Infusion Systems, driven by competitive wins and customer utilization. The company aims for a 43% gross margin by 2027, with potential for earlier achievement. FDA requested additional testing for MedFusion 5,000 syringe pump and ambulatory pump submissions. Management discussed macroeconomic challenges, currency impacts, and strategic initiatives like the Otsuka joint venture.

$ICUIHigh

ICU Medical Q3 Earnings Call Highlights

ICU Medical (ICUI) reported Q3 earnings, noting delayed Infusion Systems volume and revised growth expectations. Vital Care revenue declined 12% due to logistics issues, with full-year decline expected to be larger than anticipated. Adjusted gross margin expanded to 42%, with debt reduction continuing. The company maintained 2026 guidance but lowered capital spending forecasts.

$ICUIHighAI 8/10

ICU Medical: Q3 Earnings Snapshot

ICU Medical Inc. (ICUI) reported Q3 net income of $26.8M, or $1.07 per share, beating estimates. Adjusted EPS was $2.44, and revenue was $560.4M, also exceeding forecasts. The company expects full-year EPS of $8.60-$9.00.